PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 16, 1997Circulation135 citations

β2-Adrenergic Receptor Antagonists Protect Against Ventricular Fibrillation

View Full Paper
GBGeorge E. BillmanLCLourdes CastilloCHCharlene M. Hohl

Key Points

  • To determine whether beta2-adrenergic receptor activation provokes malignant arrhythmias via intracellular calcium surges and whether selective receptor blockade prevents ventricular fibrillation.
  • Tested 28 dogs with healed anterior myocardial infarctions during exercise-plus-ischemia protocols before and after treatment with the beta2-receptor antagonist ICI 118,551 (0.2 mg/kg), including pacing controls (n=3).

Structured PICO

P
Population
28 dogs with healed anterior myocardial infarctions (17 susceptible to ventricular fibrillation, 11 resistant) and ventricular myocytes prepared from these animals.
I
Intervention
Beta2-adrenergic receptor antagonist ICI 118,551 (0.2 mg/kg) administered prior to exercise and ischemia; in vitro exposure of myocytes to zinterol and isoproterenol with/without antagonists.
C
Comparator
Baseline response without ICI 118,551 (within-subject comparison) and comparison between susceptible versus resistant animals.
O
Outcome
Induction of ventricular fibrillation during a 2-minute occlusion of the left circumflex coronary artery during exercise.surrogate

Beta2-adrenergic receptor blockade prevents ventricular fibrillation in a canine model of healed myocardial infarction, likely by attenuating cytosolic calcium transient increases.

Abstract

BACKGROUND: The ventricular myocardium contains functional beta2-adrenergic receptors that when activated increase intracellular Ca2+ transients. Because elevated Ca2+ has been implicated in the induction of ventricular fibrillation (VF), it is possible that the activation of these receptors may also provoke malignant arrhythmias. METHODS AND RESULTS: To test this hypothesis, a 2-minute occlusion of the left circumflex coronary artery was made during the last minute of exercise in 28 dogs with healed anterior myocardial infarctions: 17 had VF (susceptible) and 11 did not (resistant). On a subsequent day, this test was repeated after administration of the beta2-adrenergic receptor antagonist ICI 118,551 (0.2 mg/kg). This drug did not alter the hemodynamic response to the coronary occlusion, yet it prevented VF in 10 of 11 animals tested (P<.001). However, heart rate was reduced in 6 animals. Therefore, the ICI 118,551 exercise-plus-ischemia test was repeated with heart rate held constant by ventricular pacing (n=3). ICI 118,551 still prevented VF when heart rate was maintained. Next, the effects of increasing doses of the beta2-adrenergic receptor agonist zinterol on Ca2+ transient amplitudes were examined in ventricular myocytes. Zinterol elicited significantly greater increases in Ca2+ transient amplitudes at all doses tested (10(-9) to 10(-6) mol/L) in myocytes prepared from susceptible versus resistant animals. The cardiomyocyte response to isoproterenol (10(-7) mol/L) in the presence or absence of the selective beta1- (CGP-20712A, 300 nmol/L) or beta2- (ICI 118,551, 100 nmol/L) adrenergic receptor antagonist was also examined. Isoproterenol elicited larger Ca2+ transient increases in the susceptible myocytes, which were eliminated by ICI but not by CGP. CONCLUSIONS: When considered together, these data demonstrate that canine myocytes contain functional beta2-adrenergic receptors that are activated to a greater extent in the susceptible animals. The resulting cytosolic Ca2+ transient increases may lead to afterpotentials that ultimately trigger VF in these animals.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Billman et al. (1997) studied this question.

synapsesocial.com/papers/6a7f22f8eadf0d493516c07fhttps://doi.org/10.1161/01.cir.96.6.1914
Ask AI
Helpful
Bookmark
Share
View Full Paper